Literature DB >> 6202753

Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia.

J P Donnelly, I D Starke, D A Galton, D Catovsky, J M Goldman, J H Darrell.   

Abstract

Forty-eight neutropenic patients with acute leukaemia were randomly allocated to receive, as antifungal prophylaxis, either ketoconazole, 400 mg once daily (K), or amphotericin B tablets and lozenges (A), or both ketoconazole and amphotericin B together (K + A). Antifungal prophylaxis was considered to have failed if (1) there was evidence of increasing colonization of the oropharynx or faeces with Candida spp. or other yeasts, or (2) if systemic antifungal therapy was begun empirically. Prophylaxis failed in nine of 17 patients given K, in four of 19 given A, and in four of 12 given K + A. The differences between the three regimens were not statistically significant, neither was there any significant difference in the mean duration of neutropenia before prophylaxis failed. The absorption of ketoconazole was impaired when patients were neutropenic. We conclude that ketoconazole was neither more nor less effective than amphotericin B in the prevention of yeast colonization in neutropenic patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202753     DOI: 10.1016/0195-6701(84)90105-1

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  12 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

Authors:  Oliver A Cornely; Angelika Böhme; Dieter Buchheidt; Hermann Einsele; Werner J Heinz; Meinolf Karthaus; Stefan W Krause; William Krüger; Georg Maschmeyer; Olaf Penack; Jörg Ritter; Markus Ruhnke; Michael Sandherr; Michal Sieniawski; Jörg-Janne Vehreschild; Hans-Heinrich Wolf; Andrew J Ullmann
Journal:  Haematologica       Date:  2008-12-09       Impact factor: 9.941

3.  Diseases and drugs but not food decrease ketoconazole 'bioavailability'.

Authors:  T K Daneshmend
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

4.  Oral symptoms and candida in the terminally ill.

Authors:  I G Finlay
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

5.  Control of an outbreak of systemic Candida albicans.

Authors:  J P Burnie; W Lee; J D Williams; R C Matthews; F C Odds
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-19

6.  Activity of amphotericin B and intraconazole against intraphagocytic Candida albicans.

Authors:  E Ponce; J C Pechère
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

7.  Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients.

Authors:  M E Ellis; H Clink; P Ernst; M A Halim; A Padmos; D Spence; M Kalin; S M Hussain Qadri; J Burnie; W Greer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

Review 8.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

9.  Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy.

Authors:  R J Stockley; T K Daneshmend; M T Bredow; D W Warnock; M D Richardson; R R Slade
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

10.  Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Cho-Hao Lee; Chin Lin; Ching-Liang Ho; Jung-Chung Lin
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.